Current Pulmonology Reports

, Volume 4, Issue 1, pp 28–33 | Cite as

Adjunct strategies to enhance the efficacy of indwelling pleural catheters

  • Christopher R. Gilbert
  • David Feller-KopmanEmail author
Pleural Diseases and Mesothelioma (C Gary Lee, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Pleural Diseases & Mesothelioma


Malignant pleural effusion remains a distressing and unfortunately common occurrence. Pleural palliation should be focused on relieving dyspnea with as few procedures as possible. The introduction of the indwelling tunneled pleural catheter has been shown to fulfill these goals; however, it is not without limitations. The ability to potentially combine the results of a long-term pleurodesis procedure without the need for a prolonged hospitalization remains an attractive option. While no large-scale trials have been completed nor is there widespread acceptance, the introduction of “rapid” or “accelerated” pleurodesis procedures, often using tunneled indwelling pleural catheters, have the potential to significantly change the current paradigm of malignant pleural effusion management. This article reviews the current data available for “rapid” and “accelerated” pleurodesis protocols and their outcomes.


Malignant pleural effusion Pleurodesis Rapid pleurodesis Accelerodesis Aggressive pleural drainage Indwelling tunneled pleural catheter 


Compliance with ethics guidelines

Conflict of interest

Dr. Christopher Gilbert has no conflict of interest to disclose.

Dr. David Feller-Kopman reports personal fees from CareFusion, during the conduct of the study.

Human and animal rights and informed consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Supplementary material

Video 1

IPC in place with Talc Poudrage (AVI 34138 kb)


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Antony VB, Loddenkemper R, Astoul P, et al. Management of malignant pleural effusions. Eur Respir J. 2001;18:402–19.CrossRefPubMedGoogle Scholar
  2. 2.
    Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ. Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65:ii32–40.CrossRefPubMedGoogle Scholar
  3. 3.
    Chernow B, Sahn S. Carcinomatous involvement of the pleura. Am J Med. 1977;63:695–702.CrossRefPubMedGoogle Scholar
  4. 4.
    Antunes G, Neville E, Duffy J, Ali N. BTS guidelines for the management of malignant pleural effusions. Thorax. 2003;58 Suppl 2:ii29–38.CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    Simoff MJ, Lally B, Slade MG, et al. Symptom management in patients with lung cancer: diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. CHEST J. 2013;143:e455S–97.CrossRefGoogle Scholar
  6. 6.•
    Davies HE, Mishra EK, Kahan BC, et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA. 2012;307:2383–9. This randomized study compared IPCs to talc slury and found no significant differences in relief of dyspnea or quality of life, though the IPC group experienced more adverse events.CrossRefPubMedGoogle Scholar
  7. 7.
    Putnam Jr JB, Light RW, Rodriguez RM, et al. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer. 1999;86:1992–9.CrossRefPubMedGoogle Scholar
  8. 8.••
    Fysh ETH, Tremblay A, Feller-Kopman D, et al. Clinical outcomes of indwelling pleural catheter-related pleural infections: an international multicenter study. CHEST J. 2013;144:1597–602. This is the largest study investigating the risk of infection using IPCs in patients with malignant pleural effusions. In 1,021 patients the overall risk of pleural infection was 4.9 %, and overall mortality was 0.29 %. Antibiotics should cover S. aureus and gram negative infections until microbiology is confirmed. In patients who do develop pleural infection, the mortality rate is 6 %.CrossRefGoogle Scholar
  9. 9.
    Mekhaiel E, Kashyap R, Mullon JJ, Maldonado F. Infections associated with tunnelled indwelling pleural catheters in patients undergoing chemotherapy. J Bronchology Interv Pulmonol. 2013;20:299–303.CrossRefPubMedGoogle Scholar
  10. 10.
    Van Meter ME, McKee KY, Kohlwes RJ. Efficacy and safety of tunneled pleural catheters in adults with malignant pleural effusions: a systematic review. J Gen Intern Med. 2011;26:70–6.CrossRefPubMedCentralPubMedGoogle Scholar
  11. 11.
    Thomas R, Budgeon CA, Kuok YJ, et al. Catheter tract metastasis associated with indwelling pleural catheters. Chest 2014.Google Scholar
  12. 12.
    Dresler CM, Olak J, Herndon 2nd JE, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest. 2005;127:909–15.CrossRefPubMedGoogle Scholar
  13. 13.
    Gonzalez AV, Bezwada V, Beamis Jr JF, Villanueva AG. Lung injury following thoracoscopic talc insufflation: experience of a single North American center. Chest. 2010;137:1375–81.CrossRefPubMedGoogle Scholar
  14. 14.••
    Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest. 2006;129:362–8. One of the largest studies of IPC, showing efficacy in approximately 90 % of patients. Mean duration of catheter days was 56 days.CrossRefPubMedGoogle Scholar
  15. 15.
    Putnam Jr JB, Walsh GL, Swisher SG, et al. Outpatient management of malignant pleural effusion by a chronic indwelling pleural catheter. Ann Thorac Surg. 2000;69:369–75.CrossRefPubMedGoogle Scholar
  16. 16.
    Musani AI, Haas AR, Seijo L, Wilby M, Sterman DH. Outpatient management of malignant pleural effusions with small-bore, tunneled pleural catheters. Respiration. 2004;71:559–66.CrossRefPubMedGoogle Scholar
  17. 17.
    Pien GW, Gant MJ, Washam CL, Sterman DH. Use of an implantable pleural catheter for trapped lung syndrome in patients with malignant pleural effusion. Chest. 2001;119:1641–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Putnam Jr JB. Malignant pleural effusions. Surg Clin N Am. 2002;82:867–83.CrossRefPubMedGoogle Scholar
  19. 19.
    Impact of aggressive versus standard drainage regimen using a long term indwelling pleural catheter (ASAP). In:, 2014. Accessed 20140918, at
  20. 20.
    Intrapleural catheter daily versus three times a week drainage. In:, 2014. Accessed 20140918, at
  21. 21.
    MacEachern P, Tremblay A. Pleural controversy: pleurodesis versus indwelling pleural catheters for malignant effusions. Respirology. 2011;16:747–54.CrossRefPubMedGoogle Scholar
  22. 22.
    Olden AM, Holloway R. Treatment of malignant pleural effusion: PleuRx catheter or talc pleurodesis? A cost-effectiveness analysis. J Palliat Med. 2010;13:59–65.CrossRefPubMedCentralPubMedGoogle Scholar
  23. 23.
    Penz ED, Mishra EK, Davies HE, Manns BJ, Miller RF, Rahman NM. Comparing cost of indwelling pleural catheter vs. talc pleurodesis for malignant pleural effusion. Chest. 2014;146(4):991–1000.CrossRefPubMedGoogle Scholar
  24. 24.
    Spiegler P, Hurewitz A, Groth M. Rapid pleurodesis for malignant pleural effusions. Chest. 2003;123:1895–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Hsu WH, Chiang CD, Chen CY, Kwan PC, Hsu JY. Ultrasound-guided small-bore Elecath tube insertion for the rapid sclerotherapy of malignant pleural effusion. Jpn J Clin Oncol. 1998;28:187–91.CrossRefPubMedGoogle Scholar
  26. 26.
    Sartori S, Tombesi P, Tassinari D, et al. Sonographically guided small-bore chest tubes and sonographic monitoring for rapid sclerotherapy of recurrent malignant pleural effusions. J Ultrasound Med. 2004;23:1171–6.PubMedGoogle Scholar
  27. 27.
    Porcel JM, Salud A, Nabal M, Vives M, Esquerda A, Rodriguez-Panadero F. Rapid pleurodesis with doxycycline through a small-bore catheter for the treatment of metastatic malignant effusions. Support Care Cancer. 2006;14:475–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Reddy C, Ernst A, Lamb C, Feller-Kopman D. Rapid pleurodesis for malignant pleural effusions: a pilot study. Chest. 2011;139:1419–23.CrossRefPubMedGoogle Scholar
  29. 29.
    Yildirim E, Dural K, Yazkan R, et al. Rapid pleurodesis in symptomatic malignant pleural effusion. Eur J Cardiothoracic Surg. 2005;27:19–22.CrossRefGoogle Scholar
  30. 30.
    Folch E, Santacruz JF. Rapid pleurodesis: an outpatient alternative. Chest. 2011;140:1665–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Singapore General Hospital. A prospective, randomized controlled trial for a rapid pleurodesis protocol for the management of pleural effusions. NLM Identifier: NCT00758316. Bethesda (MD): In:; 2014.Google Scholar
  32. 32.
    Active Pleurodesis Catheter. 2012. Accessed 18 Sept 2014, at
  33. 33.
    Tremblay A, Stather DR, Kelly MM. Effect of repeated administration of low-dose silver nitrate for pleurodesis in a rabbit model. Respirology. 2011;16:1070–5.CrossRefPubMedGoogle Scholar
  34. 34.
    Tremblay A, Dumitriu S, Stather DR, Maceachern P, Illanes O, Kelly MM. Use of a drug eluting pleural catheter for pleurodesis. Exp Lung Res. 2012;38:475–82.CrossRefPubMedGoogle Scholar
  35. 35.
    Marchi E, Vargas FS, Acencio MM, Antonangelo L, Teixeira LR, Light RW. Low doses of silver nitrate induce pleurodesis with a limited systemic response. Respirology. 2009;14:885–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Marchi E, Vargas FS, Teixeira LR, Acencio MM, Antonangelo L, Light RW. Intrapleural low-dose silver nitrate elicits more pleural inflammation and less systemic inflammation than low-dose talc. Chest. 2005;128:1798–804.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of Pulmonary, Allergy, and Critical Care Medicine, Bronchoscopy and Interventional PulmonologyPenn State College of Medicine-Milton S. Hershey Medical CenterHersheyUSA
  2. 2.Department of Pulmonary and Critical Care Medicine, Section of Interventional PulmonologyJohns Hopkins HospitalBaltimoreUSA

Personalised recommendations